Specifically, over half of the follicular cell-derived thyroid cancers are driven by BRAF V600E, TERT promoter mutations, and/or genetic alterations in the PI3K/AKT pathway, while the major genetic driver of MTC is germline or somatic rearranged during transfection (RET) mutations [2–5]. This evidence concerns the gene RET and thyroid cancer.